GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
Maurício Reis Pedrosa, Denise Reis Franco, Hannah Waisberg Gieremek, C. Vidal, Fernanda Bronzeri, Alexia de Cassia Rocha, Luis Gabriel de Carvalho Cara, Sofia Lenzi Fogo, Freddy G. Eliaschewitz
Topics & Concepts
SemaglutideLiraglutideMedicineType 2 diabetesWeight lossGlucagon-like peptide 1 receptorDulaglutideDiabetes mellitusInternal medicineAgonistEndocrinologyObesityExenatidePharmacologyReceptorDiabetes Treatment and ManagementBariatric Surgery and OutcomesPharmacology and Obesity Treatment